Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 1 September 2009, doi:10.1136/bmj.b3485
Cite this as: BMJ 2009;339:b3485
| The first 150 words of the full text of this article appear below. |
Collins and Altman inappropriately criticise the National Institute for Health and Clinical Excellence (NICE) for not choosing QRISK to predict cardiovascular risk.1 In doing so, they do not distinguish between assessing individual cardiovascular risk (as used by clinicians) and predicting risk of cardiovascular events in an actively managed population (as used in public health planning). As most tools predicting cardiovascular risk were developed in actively managed populations, they will underestimate the risk that clinicians and patients are initially interested in: the risk if no further treatment is initiated. This distinction seems to be overlooked in most discussion of cardiovascular risk.
Most doctors would expect to explain the risk to patients were they left untreated. As with several other tools, however, QRISK was derived from a population cohort that may start additional treatments once found to have high rates of risk factors. Hence it is not surprising that it underpredicts cardiovascular
Su May Liew, research student1, Paul Glasziou, professor1
1 Centre for Evidence-Based Medicine, Department of Primary Health Care, University of Oxford OX3 7LF
su.liew@dphpc.ox.ac.uk
Read all Rapid Responses